Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 20/20 | 1.00 |
| ▸ | DRD3 | P35462 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 0.67 |
| ▸ | DRD4 | P21917 | 1/20 | 0.67 |
| ▸ | DRD5 | P21918 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17005629 | 0.83 | DRD2 (0.77) | DRD2DRD3 | |
| SCHEMBL5899231 | 0.82 | DRD2 (0.70) | DRD2DRD3HTR2ADRD1DRD4 | |
| SCHEMBL16462899 | 0.81 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL16463974 | 0.81 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL16465745 | 0.80 | DRD2 (0.72) | DRD2DRD3 | |
| SCHEMBL16463141 | 0.80 | DRD2 (1.00) | DRD2DRD3HTR2ADRD1DRD4 | |
| SCHEMBL16462668 | 0.80 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL16465428 | 0.80 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL16464169 | 0.79 | DRD2 (1.00) | DRD2DRD3 | |
| SCHEMBL16462389 | 0.79 | DRD2 (1.00) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | claimed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | claimed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | claimed |
| US-8785447-B2 | Use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-22 | — | — | US | disclosed |
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-05 | — | — | US | disclosed |
| US-7098214-B1 | Dopamine D3 receptor ligands or antagonists for use in the treatment of renal function disorders | ABBOTT GMBH & CO. KG (DE) | 2006-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223793-A1 | USE OF DOPAMINE D3 RECEPTOR LIGANDS FOR THE PRODUCTION OF DRUGS FOR TREATING RENAL FUNCTION DISORDERS | SLC6A3, DRD3, DRD2 | DRD2 3/4885DRD3 2/4885HTR2A 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.